INTRODUCTION
Several authorities have called attention to the morbidity, mortality and excess health costs associated with antibiotic-resistant pathogens and the need to prioritize development of antibacterial agents that can safely and effectively treat these pathogens [1] [2] [3] [4] .
Ceftaroline fosamil is a novel cephalosporin, with bactericidal in vitro activity against pathogens associated with licensed indications, including resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Streptococcus pneumoniae (MDRSP) and penicillin-resistant S. pneumoniae (PRSP) [5] . Supported by preclinical in vitro and animal model studies [6] [7] [8] [9] [10] for the treatment of adults with communityacquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible organisms [5] .
Ceftaroline fosamil is the newest of only three Products for Human Use [16] . This report reviews the recent literature published on ceftaroline fosamil, including the pivotal clinical trials that led to its approval, and highlights areas that need to be addressed in the future.
MECHANISM OF ACTION AND SPECTRUM OF ACTIVITY
Similar to other b-lactam antibiotics, ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, mediates its bactericidal effect by binding to membranebound enzymes known as penicillin-binding proteins (PBPs), thereby interfering with bacterial cell wall synthesis and leading to cell lysis and death [17] . Distinguishing it from other b-lactam antibiotics, however, is its unique high binding affinity for PBP 2a (which confers resistance to MRSA) and PBP 2b, 2x and 1a (which confer resistance to PRSP) [18, 19] .
The favorable activity of ceftaroline against clinical isolates, including potent activity against Gram-positive bacteria, such as MRSA, vancomycin-intermediate S. aureus (VISA) and PRSP, has been demonstrated in isolates collected worldwide [20] with corroboration from a number of in vitro and in vivo studies [6, 10, [21] [22] [23] [24] [25] [26] , and maintained during in vitro attempts to generate resistant strains [27, 28] .
Activity against Enterococcus faecalis and
Enterococcus faecium is limited [6, 20 ].
Ceftaroline's spectrum of activity against Gram-negative bacteria is comparable to that of many other cephalosporins, and it has no activity against extended-spectrum b-lactamase (ESBL) and carbapenemase-producing strains (e.g., Klebsiella pneumonia carbapenemase) or strains with stable de-repressed AmpC blactamase production [20, 27, 29] . In vitro activity against Gram-positive anaerobes is similar to that of amoxicillin-clavulanate, with good activity against Propionibacterium spp. erythromycin, tetracycline, levofloxacin, and trimethoprim-sulfamethoxazole) and the frequency of non-susceptibility of respiratory pathogens to ceftaroline did not vary significantly [37, 38] . Geographic differences in activity among staphylococci, streptococci, Haemophilus spp., and Moraxella catarrhalis were minimal [39] . Susceptibility patterns to Table 1 Food and Drug Administration (FDA), Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive minimum inhibitory concentration breakpoints (lg/mL) for ceftaroline [5, 32, 33] Organism FDA a CLSI EUCAST 1092 [42] 331 [42] 460 [42] d 799 [40] 130 [40] 515 [40] 323 [42] MIC 50 413 [41] 211 [41] 113 [41] d 616 [41] 202 [41] 453 [41] 137 [41] MIC 50 
DOSE AND ADMINISTRATION
Following administration, the water-soluble prodrug, ceftaroline fosamil, is rapidly dephosphorylated to the active form in plasma [17] . For adults 18 years and older, the recommended dose is 600 mg administered intravenously (IV) over 1 h every 12 h. A treatment duration of 5-7 days for CABP and 5-14 days for ABSSSI is currently recommended, guided by the severity of infection and clinical response [5] . As with other b-lactam antibiotics, time above the MIC is the pharmacodynamic (PD) index that correlates best with efficacy [5] .
Pharmacokinetic (PK) data in healthy adults with normal renal function following multiple doses administered every 12 h over 14 days
show that the elimination half-life is about 2.7 h, the maximum observed concentration (C max ) is 21 lg/mL and the area under the concentration-time curve is 56 lg h/mL, with no appreciable accumulation [5] . Ceftaroline is primarily renally excreted and dosage adjustment is recommended for patients with creatinine clearance (CR CL ) B50 mL/min. For patients with moderate renal impairment (CR CL [30 to B50 mL/min), the dose should be adjusted to 400 mg IV every 12 h. For those with severe renal impairment (CR CL C15 to B30 mL/min), the dose should be adjusted to 300 mg IV every 12 h and for patients with endstage renal disease, including those receiving hemodialysis, adjustment to 200 mg IV every 12 h after dialysis should be made [5] .
Following a single IV radiolabeled dose, approximately 88% of radioactivity was recovered in urine and 6% in feces within 48 h [5] . Of the radioactivity recovered in urine, 64% was excreted as ceftaroline and approximately 2% as the microbiologically inactive ceftaroline M-1 metabolite, suggesting complete transformation of the prodrug [5] . Ceftaroline is primarily distributed in extracellular fluid and binding to plasma proteins is relatively low (approximately 20%) [5] . In vitro studies demonstrate that ceftaroline is not a substrate for the cytochrome P450 system and it does not inhibit or induce the major cytochrome P450 isoenzymes. Therefore, there is minimal potential for drug-drug interactions between ceftaroline and drugs that are cytochrome P450 substrates, inhibitors, or inducers [5] .
CLINICAL EFFICACY

The FOCUS Trials
The FOCUS (ceFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalized patients) 1 and 2 studies (NCT00621504 and NCT00509106, respectively) were multinational, multicenter, phase 3, double-masked, randomized, active comparator-controlled trials, designed to evaluate the safety and Baseline characteristics and demographics were comparable between the two study arms and between the two studies.
The majority of participants were Caucasian males over the age of 50 years recruited from Eastern and Western Europe. The most common pathogens isolated were S. pneumoniae (41.7%) and S. aureus (16.5%), followed by Gram-negative organisms, of which H. influenzae was the most frequent [44] .
Clinical cure rates favored ceftaroline in a priori-defined integrated analysis of the MITTE and CE populations ( [44] .
The efficacy of ceftaroline against MRSA could not be evaluated as patients with suspected MRSA infection were excluded from enrollment (due to a lack of activity of ceftriaxone against MRSA). For bacteremia, cure rates were 71.4%
(15 of 21 subjects) compared with 58.8% (10 of 17 subjects) for the ceftaroline and ceftriaxone groups, respectively (difference 12.6%, 95% CI -17.6% to 41.6%) [44] . At the late follow-up visit (21-35 days after completion of therapy), relapse rates between the two treatment arms were similar in the CE population: 1.9% for the ceftaroline group and 1.2% for the ceftriaxone group (difference 0.7%, 95% CI -1.4% to 2.9%) [44] . Pooled post hoc exploratory analysis requested by the FDA to assess clinical improvement on day 4 of study therapy in participants with a confirmed bacterial pathogen at baseline showed a weighted difference in clinical response of 11.4% (95% CI 0.6-21.9%) in favor of ceftaroline [48] .
The CANVAS Trials
The CANVAS (CeftAroliNe Versus vAncomycin in Skin and skin structure infections) 1 and 2 studies (NCT00424190 and NCT00423657, respectively) were multinational, multicenter, Baseline characteristics and demographics were comparable between the two study arms in each study. The majority of participants were Caucasian males with a median age of 48 years diagnosed with cellulitis, major abscesses and infected wounds/ulcers. Of the 76% of subjects with a pathogen isolated, S. aureus was the most common; the proportion with MRSA was 40% in the ceftaroline group and 34% in the vancomycin plus aztreonam group. Aztreonam or a saline placebo was discontinued if a Gramnegative pathogen was not identified.
A priori-defined integrated analysis of the primary endpoints demonstrated noninferiority of ceftaroline in the MITT and CE populations (Table 3 ). In a planned secondary analysis of participants in the CE population with at least one pathogen isolated, clinical cure was achieved in 92.7% of the subjects in the ceftaroline treatment group compared with and 0.9% in the ceftaroline and combination groups, respectively [47] . Post hoc analysis requested by the FDA to evaluate clinical response with cessation of lesion spread and apyrexia on day 3 of study therapy was conducted in a subgroup of 797 subjects and showed a weighted difference of 7.7% (95% CI 1.3-14.0%) in favor of ceftaroline [49] .
SAFETY
The safety profile of ceftaroline fosamil was evaluated in 1,740 participants and no unexpected safety concerns were identified [5, 48, 50, 51] . In the integrated FOCUS analysis, the most common adverse events occurring in greater than 2% of subjects receiving ceftaroline fosamil were diarrhea (4.2%), headache (3.4%), insomnia (3.1%) and phlebitis (2.8%) [50] . In the integrated CANVAS analysis, the most common adverse events occurring in greater than 2% of subjects receiving ceftaroline fosamil were nausea (5.9%), headache (5.2%), diarrhea (4.9%), pruritus (3.5%), rash (3.2%), generalized pruritus (2.2%) and dizziness (2.0%) [51] . Seroconversion to a positive direct anti-globulin (Coombs) test for the pooled data was higher in the ceftaroline group than comparator groups (10.7% vs. 4.4%, respectively), but was not associated with clinical hemolytic anemia [48] . Potential allergic reactions occurred in 5.4% of those treated with ceftaroline fosamil compared with 8.5% of those treated with a comparator regimen, 0.2% and 0.4% of these reactions were assessed as severe, respectively [48] Renal toxicity occurred in less than 2% and hepatic toxicity in less than 3% of those treated with ceftaroline fosamil. Clostridium difficileassociated diarrhea and seizures were reported, but were rare [48] .
Investigation of the effect of ceftaroline on human intestinal flora in adults who received infusions of ceftaroline fosamil IV every 12 h for 7 days revealed moderate decreases in the numbers of bifidobacteria and lactobacilli, with converse increases in the numbers of Clostridium spp., but minimal to no impact on Bacteroides spp. and aerobic bacteria [52] . Toxinproducing strains of C. difficile were isolated from two asymptomatic subjects. No measurable fecal concentrations of ceftaroline were found, which may have helped to explain the limited ecological disruptions observed [52] . At a dose of 1,500 mg, there was no clinically meaningful effect of ceftaroline fosamil on the QT interval [53] . There is no evidence of teratogenicity in animal studies, but controlled studies in pregnant or lactating women have not been performed [5] . Recently, isolated cases of eosinophilic pneumonia [54] and neutropenia [55] have been reported in patients receiving prolonged courses of ceftaroline; both events have been previously documented with cephalosporin use [56] [57] [58] [59] [60] .
Overall, the cumulative data to date suggest that ceftaroline is well tolerated with a favorable safety profile, similar to the other drugs in the cephalosporin class.
DISCUSSION
Current Role
There is a need for alternative antimicrobials that can safely and effectively treat common but serious bacterial infections, such as complicated skin and skin structure infections and CABP caused by emergent antibiotic-resistant pathogens. In 2005, there were over 14 million outpatient visits made in the USA for ABSSSIs [61] , which were among the most rapidly increasing reasons for hospitalizations between 1997 and 2007 [62] [63] [64] , correlating with the rapid increase in the incidence of communityacquired MRSA infections between the mid1990s and 2005 [65] . There has been a great reliance on the glycopeptide, vancomycin, to treat MRSA, one of the most common pathogens associated with ABSSSIs, but resistant strains, including vancomycin-resistant S. aureus (VRSA) and VISA, have emerged [66] . In addition, the rate of treatment failure is higher in strains with an MIC of 1 lg/mL or greater, which includes some strains that would be classified as susceptible using current guidelines [67] . Vancomycin may also be inferior to b-lactam antibiotics for the treatment of methicillinsusceptible S. aureus bacteremia [68] bone and joint penetration [85] . Ceftaroline was superior to cefepime against Klebsiella pneumoniae in a rabbit meningitis model; the penetration of ceftaroline into inflamed and non-inflamed meninges was estimated to be 15% and 3%, respectively [86] .
Reports of off-label use of ceftaroline are also emerging. Prompt sterilization of blood following the addition of ceftaroline salvage therapy was documented in a review of six cases of persistent or recurrent MRSA bacteremia/ endocarditis being treated with vancomycin or daptomycin [87, 88] . Interestingly, the five patients treated with a more aggressive regimen of ceftaroline 600 mg administered every 8 h all survived, while the patient who received ceftaroline every 12 h succumbed to other complications [87] . A case report documented clearance of blood within 4 days of the addition of ceftaroline in a patient with endocarditis failing daptomycin therapy, and is supported by an in vitro PK/PD model, which
showed that the addition of ceftaroline enhances daptomycin susceptibility [88] . A similar PK/PD model showed that ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycinsusceptible and non-susceptible strains of MRSA, suggesting potency of this combination [89] . Ceftaroline has also been used for the treatment of prosthetic joint infections [90] and in a patient with osteomyelitis and endocarditis In 
